It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The WWE domain is a relatively under-researched domain found in twelve human proteins and characterized by a conserved tryptophan-tryptophan-glutamate (WWE) sequence motif. Six of these WWE domain-containing proteins also contain domains with E3 ubiquitin ligase activity. The general recognition of poly-ADP-ribosylated substrates by WWE domains suggests a potential avenue for development of Proteolysis-Targeting Chimeras (PROTACs). Here, we present novel crystal structures of the HUWE1, TRIP12, and DTX1 WWE domains in complex with PAR building blocks and their analogs, thus enabling a comprehensive analysis of the PAR binding site structural diversity. Furthermore, we introduce a versatile toolbox of biophysical and biochemical assays for the discovery and characterization of novel WWE domain binders, including fluorescence polarization-based PAR binding and displacement assays, 15N-NMR-based binding affinity assays and 19F-NMR-based competition assays. Through these assays, we have characterized the binding of monomeric iso-ADP-ribose (iso-ADPr) and its nucleotide analogs with the aforementioned WWE proteins. Finally, we have utilized the assay toolbox to screen a small molecule fragment library leading to the successful discovery of novel ligands targeting the HUWE1 WWE domain.
Six WWE domain-containing proteins also contain domains with E3 ubiquitin ligase activity. We report structures, biophysical and biochemical assays for the discovery of novel WWE domain binders and their respective application.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details








1 Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria (GRID:grid.486422.e) (ISNI:0000000405446183)
2 University of Toronto, Structural Genomics Consortium, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938); Princess Margaret Cancer Centre, Toronto, Canada (GRID:grid.415224.4) (ISNI:0000 0001 2150 066X)
3 University of Oxford, Centre for Medicines Discovery, Nuffield Department of Medicine, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
4 University of Toronto, Structural Genomics Consortium, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938)
5 Johns Hopkins University, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311)
6 University of Toronto, Structural Genomics Consortium, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938); Princess Margaret Cancer Centre, Toronto, Canada (GRID:grid.415224.4) (ISNI:0000 0001 2150 066X); University of Toronto, Department of Medical Biophysics, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938)
7 University of Toronto, Structural Genomics Consortium, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938); University of Toronto, Department of Pharmacology and Toxicology, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938)